DisruptionJul 15, 2026, 09:51 AM
Dr. Reddy's Halts Semaglutide Injection Supply Due to Impurity
AI Summary
Dr. Reddy's Laboratories announced a temporary halt in commercial supplies of its Semaglutide injection due to an impurity found out of specifications during the scale-up of the synthetic API manufacturing process. This issue, which caused degradation during formulation testing of validation batches, will delay supplies until late October/early November 2026. The company now targets supplying 6-7 million pens between Q3 and Q4 FY27 (November to March). Dr. Reddy's emphasized there is no impact on patient safety for products already supplied, no changes to regulatory filings, and no effect on Semaglutide oral tablets.
Key Highlights
- Temporary halt in commercial supplies of Semaglutide injection.
- Impurity found out of specifications during API scale-up validation.
- Expected resumption of commercial supply to partner OneSource in October 2026.
- Target supply of 6-7 million Semaglutide pens between Q3 and Q4 FY27 (Nov-Mar).
- No patient safety impact for product already supplied to market.
- No impact on existing global regulatory filings or Semaglutide oral tablets.
- Issue is process-related, requiring parameter tweaking and re-validation.
- Backup injectable API supplier qualification would take approximately one year.
Price Impact
More from RDY